Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorHATLEBERG, C. I.
dc.contributor.authorRYOM, L.
dc.contributor.authorEL-SADR, W.
dc.contributor.authorMOCROFT, A.
dc.contributor.authorREISS, P.
dc.contributor.authorDE WIT, S.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDABIS, Francois
dc.contributor.authorPRADIER, C.
dc.contributor.authorD'ARMINIO MONFORTE, A.
dc.contributor.authorKOVARI, H.
dc.contributor.authorLAW, M.
dc.contributor.authorLUNDGREN, J. D.
dc.contributor.authorSABIN, C. A.
dc.date.accessioned2020-11-16T11:12:33Z
dc.date.available2020-11-16T11:12:33Z
dc.date.issued2018-03
dc.identifier.issn1758-2652 (Electronic) 1758-2652 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/14024
dc.description.abstractEnINTRODUCTION: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) among HIV-positive individuals. We investigated whether such differences exist in the observational D:A:D cohort study. METHODS: Participants were followed from study enrolment until the earliest of death, six months after last visit or February 1, 2015. Initiation of CVD interventions [lipid-lowering drugs (LLDs), angiotensin-converting enzyme inhibitors (ACEIs), anti-hypertensives, invasive cardiovascular procedures (ICPs) were investigated and Poisson regression models calculated whether rates were lower among women than men, adjusting for potential confounders. RESULTS: Women (n = 12,955) were generally at lower CVD risk than men (n = 36,094). Overall, initiation rates of CVD interventions were lower in women than men; LLDs: incidence rate 1.28 [1.21, 1.35] vs. 2.40 [2.34, 2.46]; ACEIs: 0.88 [0.82, 0.93] vs. 1.43 [1.39, 1.48]; anti-hypertensives: 1.40 [1.33, 1.47] vs. 1.72 [1.68, 1.77] and ICPs: 0.08 [0.06, 0.10] vs. 0.30 [0.28, 0.32], and this was also true for most CVD interventions when exclusively considering periods of follow-up for which individuals were at high CVD risk. In fully adjusted models, women were less likely to receive CVD interventions than men (LLDs: relative rate 0.83 [0.78, 0.88]; ACEIs: 0.93 [0.86, 1.01]; ICPs: 0.54 [0.43, 0.68]), except for the receipt of anti-hypertensives (1.17 [1.10, 1.25]). CONCLUSION: The use of most CVD interventions was lower among women than men. Interventions are needed to ensure that all HIV-positive persons, particularly women, are appropriately monitored for CVD and, if required, receive appropriate CVD interventions.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.subject.enMORPH3Eus
dc.subject.enDAD
dc.title.enGender differences in the use of cardiovascular interventions in HIV-positive persons
dc.title.alternativeJ Int AIDS Socen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/jia2.25083en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29509305en_US
bordeaux.journalJournal of the International AIDS Societyen_US
bordeaux.volume3en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.teamDADen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03007322
hal.version1
hal.date.transferred2020-11-16T11:12:37Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20the%20International%20AIDS%20Society&rft.date=2018-03&rft.volume=3&rft.eissn=1758-2652%20(Electronic)%201758-2652%20(Linking)&rft.issn=1758-2652%20(Electronic)%201758-2652%20(Linking)&rft.au=HATLEBERG,%20C.%20I.&RYOM,%20L.&EL-SADR,%20W.&MOCROFT,%20A.&REISS,%20P.&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem